Condition: Renal Impairment · Sponsor: Noucor Health S.A.
The purpose of this study is to assess the PK, tolerability, and safety of rupatadine (10 mg) and its active metabolites in participants with renal impairment compared to matched control participants with normal renal function. The study duration will be up to 40 days, including Screening, Baseline, Study Period, and EOS visit assessments. Rupatadine 10 mg tablet will be administered as single dose.
This description comes directly from the study's public registry record.
Daniel Peris, PharmD · +34937376690 · daniel.peris@noucor.com
Laia Casas, MSc · +34937376690 · laia.casas@noucor.com
Always discuss trial participation with your own doctor first.
| Centro Hospitalar De Vila Nova De Gaia Espinho | Gaia, Portugal | Recruiting |
| Hospital Pedro Hispano | Matosinhos Municipality, Portugal | Recruiting |
| Blueclinical Investigacao E Desenvolvimento Em Saude Lda. | Porto, Portugal | Recruiting |
| Hospital Universitari Germans Trias I Pujol | Badalona, Spain | Recruiting |
| Municipal Institute Of Medical Investigation | Barcelona, Spain | Recruiting |
| Hospital De La Santa Creu I Sant Pau | Barcelona, Spain | Recruiting |
| Hospital Universitario De La Princesa | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06708520